Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Thyroid Eye Disease News
US FDA Grants Breakthrough Status to Viridian’s Thyroid Eye Disease Candidate
Viridian Therapeutics announced May 7 that the US FDA had granted breakthrough therapy status to veligrotug, the company’s anti-insulin-like growth factor-1 receptor (IGF-1R) candidate for thyroid ...
Q1-2025 Ophthalmic Revenue Roundup for Amgen, Hoya, Apellis, Tarsus, STAAR, RxSight, and Ocular Therapeutix
Amgen, of Thousand Oaks, California, reported May 1 that its Q1-2025 revenue from Tepezza was $381 million, a 10 percent decrease from $424 million in Q1-2024. The total consisted of $365 million...
Emerging Companies Pursuing Ophthalmic Indications, April 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
April 2025 Ophthalmic News Briefs
Carl Zeiss Meditec announced March 21 the availability in Canada of the Visulas Combi, a green and YAG ophthalmic laser workstation combining photodisruption, photocoagulation, and slit lamp techno...
Chinese Regulators Approve Innovent’s Sycume for Thyroid Eye Disease
China’s Innovent Biologics announced March 14 that Chinese regulators had approved Sycume, a recombinant anti-insulin-like growth factor 1 receptor antibody for thyroid eye disease (TED). Innovent ...
2024 Ophthalmic Revenue Roundup for Amgen and Biogen
Amgen, of Thousand Oaks, California, reported Feb. 4 that its 2024 revenue for Tepezza was $1.85 billion. 2024 was the first full year of Tepezza sales for Amgen after the company closed its acquis...
Japanese Regulators Grant Orphan Drug Status to HanAll’s Batoclimab in Active Thyroid Eye Disease
South Korea’s HanAll Biopharma announced March 6 that Japanese regulators had granted orphan drug designation to batoclimab, a subcutaneous anti-FcRn treatment being developed for autoimmune diseas...
Clinical Trial Updates for Ophthalmic Candidates, February 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Acelyrin to Merge with Alumis in All-Stock Transaction
Acelyrin, which was developing lonigutamab, a subcutaneous treatment candidate for thyroid eye disease (TED), announced Feb. 6 that it would merge with Alumis in an all-stock transaction. The combi...
Clinical Trial Updates for Ophthalmic Candidates, January 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Tepezza Receives Approval in Japan to Treat Active Thyroid Eye Disease
Amgen reported Sept. 24 that Tepezza had gained approval in Japan for the treatment of active or high clinical activity score thyroid eye disease (TED). The Thousand Oaks, California, company said ...
Acelyrin Shifts Pipeline to Focus on TED Candidate, Lays Off About 40 Workers
Acelyrin reported Aug. 13 that it would reduce its workforce and shift its pipeline strategy to prioritize lonigutamab, its candidate for thyroid eye disease (TED). The announcement came amid posit...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.